Literature DB >> 2835437

Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect.

S Mossman1, A Vincent, J Newsom-Davis.   

Abstract

The effects of serum Ig from 7 myasthenia gravis patients on neuromuscular transmission was investigated by passive transfer to mice. A protocol of 60 mg/day for 3 days produced mouse serum levels of anti-mouse AChR that were similar to those in the MG patients, and resulted in corresponding levels (2-76%) of mouse muscle AChR with antibody bound in situ. However, AChR loss was only greater than 20% with one MG preparation. Nevertheless, there was a marked neuromuscular defect in mice injected with 3 preparations which did not necessarily correlate with the degree of AChR loss or the amount of AChRs with antibody bound in situ. We conclude that in some MG patients part of the defect in neuromuscular transmission may result from antibodies binding to other components of the neuromuscular junction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835437     DOI: 10.1016/0022-510x(88)90170-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

2.  Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice.

Authors:  L Jacobson; A Polizzi; G Morriss-Kay; A Vincent
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 3.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

4.  Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.

Authors:  Gregory Kordas; George Lagoumintzis; Sotirios Sideris; Konstantinos Poulas; Socrates J Tzartos
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

5.  Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications.

Authors:  Kaori Noridomi; Go Watanabe; Melissa N Hansen; Gye Won Han; Lin Chen
Journal:  Elife       Date:  2017-04-25       Impact factor: 8.140

Review 6.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.